ClinicalTrials.gg
TerminatedNCT02722603GABA-1Updated Oct 3, 2019

Study to Compare Gabapentin to Tramadol in Children With Chronic Neuropathic or Mixed Pain

A Phase 3 interventional study of gabapentin and tramadol in Chronic Pain, sponsored by Pharmaceutical Research Management srl. Terminated at 2 sites in 2 countries. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2019-10-03.

Sponsored by Pharmaceutical Research Management srl · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was early terminated due to insufficient recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
3 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing gabapentin in Chronic Pain — none open to participants now, none under way, none of them phase 3. Gabapentin · Chronic Pain.

Enrollment
8th of 10
2 · median 43
Started
2018
with 1 other
Phase 3
3 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
2 of 10
Pharmaceutical Research Management srl

Among the 10 studies testing gabapentin in Chronic Pain, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 4th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

None of the 10 studies testing gabapentin in Chronic Pain is open now. The open studies under Chronic Pain, anywhere →

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 3 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing gabapentin in Chronic Pain as a file.
02

Study summary

This study evaluates the efficacy and safety of gabapentin relative to tramadol for the treatment of chronic, neuropathic or mixed pain in the paediatric population. Children from 3 months to less than 18 years of age experiencing moderate to severe chronic pain will receive either gabapentin or tramadol for 15 weeks. The difference in average pain scores between treatment arms at the end of the treatment period will be assessed.

Read the detailed description

Gabapentin is indicated for the treatment of peripheral neuropathic pain in adults. In the absence of specific paediatric studies, it is not approved for the same condition in children.

The paediatric use of gabapentin is hampered by a) the lack of a suitable paediatric formulation, b) the significant variability of gabapentin pharmacokinetics profile and c) efficacy and safety data in this specific population.

The GABA-1 study is designed to demonstrate the efficacy of gabapentin oral solution relative to tramadol and to document the Pharmacokinetic and safety profile of gabapentin in this indication.

GABA-1 is a non-inferiority trial because gabapentin is expected to be equally effective but better tolerated than tramadol, thus providing a clinical benefit to affected children.

03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
3 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 3 months to less than 18 years at screening.
  2. by parent(s) and/or legal guardian according to each country legal requirement.
  3. Assent by the patient, where applicable, according to each country legal requirement.
  4. Subjects that meet the diagnostic criteria for neuropathic or mixed pain.
  5. Subjects that present with chronic pain defined as the recurrent or continuous pain persisting more than 3 months. Duration of pain will be determined from the date of the first pain experienced.
  6. Subjects that present with at least moderate pain as defined by average pain intensity of ≥4/10 as assessed during a 3-day screening period
  7. Stable underlying disease condition and treatment.
  8. In presence of malignant diseases, subjects in clinical remission and/or no expected changes in their therapeutic protocol during participation to the present study.

Exclusion criteria

Exclusion Criteria:

  1. Pain duration of more than 5 years.
  2. Current use of gabapentin or tramadol.
  3. History of failure to respond to adequate treatment by gabapentin or tramadol/opioids for neuropathic pain.
  4. History of epileptic condition except febrile seizure disorder.
  5. Subjects with sleeping apnoea syndrome of any origin or subjects with history of severe respiratory impairment.
  6. Subjects with diagnosis of sickle cell disease.
  7. Subjects that present significant cognitive impairment.
  8. Subjects that present current, controlled or uncontrolled, co-morbid psychiatric diagnosis that can impair pain diagnosis and assessment such as severe depressive conditions or psychosis.
  9. Subjects with history of suicidal ideation or behaviour.
  10. History of substance abuse in particular opioids.
  11. Subjects under prohibited concomitant medication
  12. Subjects in need for oral treatment or corticosteroid infiltrations to treat pain caused by infiltration or compression of neural structures, e.g. peripheral nerves or spinal cord.
  13. Subjects born prematurely at ≤ 36 weeks gestational age, if recruited during the first year of age.
  14. Subjects with a (BMI) for age and gender of \< 5th percentile or > 95th percentile.
  15. Subjects with \< 90 mL/min/1.73 m2 (Schwarz equation).
  16. Subjects with significant hepatic impairment or with (AST) or Alanine Transaminase (ALT) enzymes 3 times the upper limit of the age-specific reference range.
  17. Subjects with known allergy, or intolerance to gabapentin or tramadol or any component found in the study drugs.
  18. Subjects with fructose intolerance, diabetes, glucose-galactose malabsorption or lactase-isomaltase deficiency.
  19. Subjects with clinically relevant abnormal at the screening visit in the discretion of the Investigator/cardiologist.
  20. Subjects participating in another clinical interventional trial.
  21. Subjects scheduled for surgery or in recovery from surgery occurring within 3 months of baseline assessment.
  22. Female subjects who are pregnant or currently lactating.
  23. Subjects that failed screening or were previously enrolled in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    gabapentin / placebo tramadol

    gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.

    Drug: gabapentin · Other: placebo tramadol

  • Active comparator
    tramadol / placebo gabapentin

    tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.

    Drug: tramadol · Other: placebo gabapentin

Interventions

  • 75 mg/ml gabapentin syrup

  • 100 mg/ml tramadol oral drops

  • Otherplacebo tramadol

    placebo tramadol oral drops

  • Otherplacebo gabapentin

    placebo gabapentin syrup

06

What researchers measure

Primary outcomes

  1. Pain score

    Pain score (0-10) measured at baseline (before starting the therapy) and at the end of the treatment in: patients aged 3-24 months using FLACC pain scale, patients aged 3-7 years using FPS-R scale, patients aged 8-17 years using NRS-11. The FLACC (the Faces, Legs, Arms, Cry and Consolability) scale is composed by 5 categories. Each category is scored on the 0-2 scale, which results in a total score of 0-10, where 0=Relaxed and comfortable, 4-6=Moderate pain, 1-3=Mild discomfort, 7-10=Severe discomfort or pain or both. FPS-R (Faces Pain Scale - Revised - pts aged 3-7 years). Score is associated with face 0, 2, 4, 6, 8, or 10, where 0 = no pain and 10=very much pain. NRS-11 (Numerical Rating Scale - pts aged 8-17 years): numerical rating scale where 0=no pain and 10=worst possible pain.

    Time frame: an average of 16 weeks

Secondary outcomes

  1. Percentage of responders to treatment

    Subjects with a pain intensity reduction of 30% from baseline or below or equal to 3/10, assessed by age-appropriate pain scale. FLACC (the Faces, Legs, Arms, Cry and Consolability) scale (pts aged 3-24-months) is composed by 5 categories. Each category is scored on the 0-2 scale, which results in a total score of 0-10, where 0=Relaxed and comfortable, 4-6=Moderate pain, 1-3=Mild discomfort, 7-10=Severe discomfort or pain or both. FPS-R (Faces Pain Scale - Revised - pts aged 3-7 years). Score is associated with face 0, 2, 4, 6, 8, or 10, where 0 = no pain and 10=very much pain. NRS-11 (Numerical Rating Scale - pts aged 8-17 years): numerical rating scale where 0=no pain and 10=worst possible pain.

    Time frame: an average of 16 weeks

  2. Daily pain intensity

    Daily pain intensity, assessed by age-appropriate scale (FLACC, FPS-R or NRS-11) during dose optimization. The FLACC (the Faces, Legs, Arms, Cry and Consolability) scale (pts aged 3-24-months) is composed by 5 categories. Each category is scored on the 0-2 scale, which results in a total score of 0-10, where 0=Relaxed and comfortable, 4-6=Moderate pain, 1-3=Mild discomfort, 7-10=Severe discomfort or pain or both. FPS-R (Faces Pain Scale - Revised - pts aged 3-7 years). Score is associated with face 0, 2, 4, 6, 8, or 10, where 0 = no pain and 10=very much pain. NRS-11 (Numerical Rating Scale - pts aged 8-17 years): numerical rating scale where 0=no pain and 10=worst possible pain.

    Time frame: an average of 3 weeks

  3. Observational assessment of pain

    Observational assessment of pain using the NRS-11 completed by parents and Investigator (or caregiver) at each visit. NRS-11: numerical rating scale where 0=no pain and 10=worst possible pain

    Time frame: an average of 16 weeks

  4. Self-assessment of pain for children ≥8 years of age

    Self-assessment of pain for children ≥8 years of age using the FPS-R pain scale at each visit. FPS-R (Faces Pain Scale - Revised) Score is associated with face 0, 2, 4, 6, 8, or 10, where 0 = no pain and 10=very much pain.

    Time frame: an average of 16 weeks

  5. Extent of pain

    number of painful areas using the pain charts at screening visit (V1), randomisation (v2) and EOS visit (V10). The pain charts are body maps (front and back) in which each body section is identified with a number.

    Time frame: an average of 16 weeks

  6. Number of episodes of breakthrough pain

    Number of episodes of breakthrough pain (\> 4/10 pain score and use of rescue medications) during treatment period.

    Time frame: an average of 16 weeks

  7. Number of rescue interventions

    Number of rescue interventions required during treatment period

    Time frame: an average of 15 weeks

  8. Number of pain-free days

    Number of pain-free (\< 4/10 average pain score without the use of rescue medications) days during treatment period

    Time frame: an average of 15 weeks

  9. Number of participant dropouts

    Number of participant dropouts due to lack of efficacy

    Time frame: up to 21 weeks

  10. The total cumulative weight normalized dose of each rescue drug

    The total cumulative weight normalized dose of each rescue drug

    Time frame: up to 21 weeks

  11. Total Summary Score from PedsQL™ scale

    Total score obtained using the PedsQL 4.0 Generic Core Scales (by parent, patient aged 3-17years) and PedsQL Infants Scales (by parent of pts aged 3-24months) at randomisation (V2) and at EOS (V10). The total score is a measure of Health Related Quality of life (HRQoL). Higher scores indicate better HRQOL. PedsQL 4.0 Generic Core Scales is composed by 4 multidimensional scales (Physical Funct, Emotional Funct, Social Funct, School Funct) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). Scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always). PedsQL Infant Scales is composed by 5 multidim. scales (Physical Functioning, Physical Symptoms, Emotional Functioning, Social Functioning, Cognitive Functioning) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). The scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always)

    Time frame: an average of 15 weeks

  12. Physical Health Summary Score from PedsQL™ scale

    Physical Health Score obtained using the PedsQL™ 4.0 Generic Core Scales (by parent, patient aged 3-17 years) and PedsQL™ Infant Scales (by parent, aged 3-24 months) at randomisation (V2) and at EOS (V10). PedsQL™ 4.0 Generic Core Scales is composed by 4 multidimensional scales (Physical Funct, Emotional Funct, Social Funct, School Funct) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). Scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always). PedsQL™ Infant Scales is composed by 5 multidimensional scales (Physical Functioning, Physical Symptoms, Emotional Functioning, Social Functioning, Cognitive Functioning) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). The scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always).

    Time frame: an average of 15 weeks

  13. Psychosocial Health Summary Score from PedsQL™ scale

    Psychosocial Health Score obtained using the PedsQL™ 4.0 Generic Core Scales (by parent, patient aged 3-17 years) and PedsQL™ Infant Scales (by parent, aged 3-24 months) at randomisation (V2) and at EOS (V10). PedsQL™ 4.0 Generic Core Scales is composed by 4 multidimensional scales (Physical Funct, Emotional Funct, Social Funct, School Funct) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). Scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always). PedsQL™ Infant Scales is composed by 5 multidimensional scales (Physical Functioning, Physical Symptoms, Emotional Functioning, Social Functioning, Cognitive Functioning) and 3 summary scores (Total Scale Score, Physical Health Summary Score, Psychosocial Health Summary Score). The scoring is based on a 5-point Likert scale from 0 (Never) to 4 (Almost always).

    Time frame: an average of 15 weeks

  14. Acceptability of treatment

    Acceptability of treatment (Five-Point Facial Hedonic scale) at EOS visit (V10). Each face in the scale is related to a score (1=unpleasant; 2=not sure; 3=pleasant).

    Time frame: at week 16

  15. Global satisfaction with treatment

    Global satisfaction with treatment (NRS-11, by parent, patient) at EOS visit (V10). The satisfaction is measeured by the numerical rating scale NRS-11 where 0=not satisfied and 10=fully satisfied

    Time frame: at week 15

  16. Clinical Global Impression of Severity of the subject's condition

    Clinical Global Impression of Severity (CGI-S) for Neuropathic or Mixed Pain Overall Severity Prior to Study Treatment (at randomization - V2) assessed by Investigator. Investigators will rate their impression of the severity of the subject's condition. Scoring: Normal: no signs of pain, Borderline painful, Mildly painful, Moderately painful, Markedly painful,Severely painful, Among the most extremely painful patients.

    Time frame: an average of 15 weeks

  17. Clinical Global Impression of Improvement for pain

    Clinical Global Impression of Improvement (CGI-I) for Neuropathic or Mixed Pain Overall at V6 and EOS visit (V10) assessed by Investigator. Investigators will rate their impression of any change of the subject's overall condition of neuropathic or mixed pain since randomization in the study. Scoring are: Very much improved since the initiation of treatment; Much improved; Minimally improved; No change from baseline (the initiation of treatment); Minimally worse; Much worse; Very much worse since the initiation of treatment.

    Time frame: an average of 15 weeks

  18. Patient/parent Global Impression of Change

    Patient/parent Global Impression of Change (PGIC; by parent, patient) at V6 and at EOS visit (V10). Patient/parent will rate their impression of any change of the subject's overall condition of neuropathic or mixed pain since randomization in the study. Scoring are: Very much improved since the initiation of treatment; Much improved; Minimally improved; No change from baseline (the initiation of treatment); Minimally worse; Much worse; Very much worse since the initiation of treatment.

    Time frame: an average of 12 weeks

  19. CL/F

    Primary pharmacokinetic parameters for gabapentin and tramadol: assessment of apparent clearance (CL/F) and of its variability and precision. In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  20. Vd/F

    Primary pharmacokinetic parameter for gabapentin and tramadol: assessment of apparent volume of distribution (Vd/F) and of its variability and precision. In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  21. ka

    Primary pharmacokinetic parameter for gabapentin and tramadol: assessment of absorption rate constant (Ka) and of its precision and variability. In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  22. AUC

    Secondary pharmacokinetic parameter for gabapentin and tramadol: assessment of Area under the Concentration curve (AUC). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  23. Cmax

    Secondary pharmacokinetic parameter for gabapentin and tramadol: assessment of peak plasma concentration (Cmax). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  24. Tmax

    Secondary pharmacokinetic parameter for gabapentin and tramadol: assessment of time at which the Cmax is observed (Tmax). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  25. Css

    Secondary pharmacokinetic parameter for gabapentin and tramadol: assessment of steady state Concentrations (Css). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  26. Cmin

    Secondary pharmacokinetic parameter for gabapentin and tramadol: assessment of minimum concentration (Cmin). In total, 4 samples will be collected, 1 before dosing and again at 3 different time windows post-dosing (0 - 2 h; 2 - 4 h and 4 - 6 h)

    Time frame: at week 3 or at week 4 or at week 16

  27. Systemic exposure to investigational products during maintenance period

    Systemic exposure to investigational products during maintenance period, as assessed by predicted steady-state concentrations.

    Time frame: an average of 12 weeks

  28. Incidence of Adverse Events at all visits

    Incidence of Adverse Events at all visits

    Time frame: up to 21 weeks

  29. Percentage of subjects discontinuing the trial due to treatment-emergent adverse events.

    Percentage of subjects discontinuing the trial due to treatment-emergent adverse events.

    Time frame: up to 21 weeks

  30. Aggressive behaviour in children aged >6 years

    Aggressive behaviour in children aged \>6 years using the Retrospective-Modified Overt Aggression Scale (R-MOAS) at V2, V6 and EOS visit (V10). The scale includes 4 domains (Verbal Incidents, Incidents Toward Other People, Incidents Involving Property, Incidents Directed Toward Self) each one describing different behaviours. Parents rate the frequency of 16 aggressive behaviors (referred to the past week) in the 4 areas. Numeric weighting amplifies the seriousness of more harmful behaviors in the total score. Higher score indicating more aggressive behavior.

    Time frame: an average of 15 weeks

  31. Suicidal ideation/behaviour in subjects aged 6 years and older

    Suicidal ideation/behaviour in subjects aged ≥ 6 years using the Columbia - Suicide Severity Rating Scale (C-SSRS) before IMP (screening V1), V6, EOS visit (V10) and end of taper visit (V11). The C-SSRS is divided into 2 sections: Suicidal Ideation and Suicidal Behaviour containing each one 5 "yes" or "no" questions. Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the CSSRS) present at the assessment. A score of 0 is assigned if no ideation is present. Composite endpoints are defined below: Suicidal ideation: A "yes" answer at any time during treatment to any one of the five suicidal ideation questions (Categories 1-5). Suicidal behavior: A "yes" answer at any time during treatment to any one of the five suicidal behavior questions (Categories 6-10). Suicidal ideation or behavior: A "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (Categories 1-10)

    Time frame: an average of 16 weeks

  32. Assessment of blinding

    Assessment of blinding: guess of the subject's treatment group (by Investigator, parents and subject if at adequate maturity level) at V10.

    Time frame: at week 16

07

Study locations

2 sites
  • Universitaets klinikum Erlangen
    Erlangen, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam
    Rotterdam, Netherlands
08

References and documents

Publications

  • Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep. 2010 Jul 14;2:52. doi: 10.3410/M2-52. PubMed 21170362 ↗
  • Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain. 2001 Dec;17(4):284-95. doi: 10.1097/00002508-200112000-00002. PubMed 11783808 ↗
  • Kaguelidou F, Le Roux E, Mangiarini L, Lundin R, de Leeuw TG, Della Pasqua O, Felisi M, Bonifazi D, Tibboel D, Ceci A, de Wildt SN, Alberti C; GAPP consortium. Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol. BMJ Open. 2019 Feb 20;9(2):e023296. doi: 10.1136/bmjopen-2018-023296. PubMed 30787078 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in May 2019, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2016
First posted
Mar 30, 2016
StartActual
Sep 12, 2018
Primary completionActual
May 31, 2019
CompletionActual
Jun 18, 2019
Last update
Oct 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02722603
Lead sponsor
Pharmaceutical Research Management srl
Collaborators
European Commission
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
Sep 12, 2018
Primary completion
May 31, 2019
Completion
Jun 18, 2019
Last update
Oct 3, 2019

Study contacts

Florentia Kaguelidou
principal investigator · Center Clin Investig INSERM CIC 1426 H. R Debré APH de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion